Connected Patterns: Understanding Drug Discovery Through Verification Ladders and Honest Uncertainty
“In drug discovery, optimism is cheap. Evidence is expensive.”
Drug discovery is not a single problem. It is a chain of problems.
Flagship Router PickQuad-Band WiFi 7 Gaming RouterASUS ROG Rapture GT-BE98 PRO Quad-Band WiFi 7 Gaming Router
ASUS ROG Rapture GT-BE98 PRO Quad-Band WiFi 7 Gaming Router
A flagship gaming router angle for pages about latency, wired priority, and high-end home networking for gaming setups.
- Quad-band WiFi 7
- 320MHz channel support
- Dual 10G ports
- Quad 2.5G ports
- Game acceleration features
Why it stands out
- Very strong wired and wireless spec sheet
- Premium port selection
- Useful for enthusiast gaming networks
Things to know
- Expensive
- Overkill for simpler home networks
Each link has its own uncertainties, its own failure modes, and its own incentives to overclaim. AI can help at many links, but only if you design the workflow to keep truth ahead of excitement.
The practical stance is simple:
- Use AI to generate and prioritize hypotheses
- Use experiments and rigorous evaluation to decide what is real
- Keep humans accountable for claims
This is not a limitation. It is the only way to do responsible discovery.
Where AI Actually Helps
AI tends to help most where the search space is large and the budget is limited:
- Prioritizing targets and pathways based on multi-source evidence
- Predicting properties that are expensive to measure at scale
- Proposing candidate molecules within constraints
- Ranking compounds for screening and follow-up experiments
- Detecting patterns in assay readouts and high-dimensional measurements
AI is a multiplier on decision-making.
But it does not remove uncertainty. It just moves uncertainty around.
Target Selection: The First Place to Demand Evidence
Target choice sets the direction of everything downstream.
A strong evidence-driven workflow makes target selection explicit:
- What evidence supports the target’s role in the disease mechanism?
- What evidence supports that modulating it is feasible?
- What are the known failure modes for this class of target?
- What would falsify the target hypothesis early?
AI can help map literature and data into a structured argument, but it cannot replace the responsibility of making the argument coherent and testable.
The Drug Discovery Verification Ladder
A useful way to keep the workflow honest is to name the ladder explicitly.
| Ladder rung | AI contribution | What must be verified |
|---|---|---|
| Target hypothesis | Surface candidate targets and rationales | Plausibility and independent evidence support |
| Assay design | Suggest measurable proxies and controls | Whether the assay measures what you think it measures |
| Screening and triage | Rank candidates and reduce search cost | Proper splits, bias checks, false positive auditing |
| Hit confirmation | Identify likely true hits | Orthogonal assays, replication, dose-response validation |
| Lead optimization | Propose modifications and tradeoffs | Real property measurements, feasibility, safety checks |
| Robustness | Predict outcomes and risk | External validation, uncertainty quantification, failure mode testing |
The pattern is the same: AI proposes. Verification decides.
Assays: The Place Where Many Projects Quietly Break
Assays can be deceptively fragile.
Common problems include:
- The assay proxy does not represent the mechanism you care about
- Batch effects dominate the signal
- The readout saturates or is sensitive to minor protocol drift
- The label is ambiguous or noisy in ways that the model cannot see
A disciplined team treats assay design as a scientific claim in its own right. If the assay is wrong, AI will accelerate the wrong thing.
The Most Common Trap: Leakage Disguised as Performance
Drug discovery datasets are full of subtle leakage:
- Highly similar compounds across train and test
- Repeated measurements and near-duplicates
- Shared experimental artifacts that correlate with the label
- Benchmark splits that do not reflect real-world generalization
If you evaluate with random splits, you can get strong metrics that collapse in practice.
More realistic evaluation practices include:
- Holding out entire scaffolds or families
- Holding out assay batches or labs when possible
- Keeping a locked external test set that is not touched until late
- Auditing nearest neighbors for every top candidate
If your evaluation does not match deployment, your metrics are storytelling.
A Practical Pipeline That Respects Reality
A strong pipeline is a loop that ties model outputs to experiments and learning.
A workable flow looks like this:
- Define the success criteria and constraints for the current stage
- Gather data with provenance, including negative outcomes
- Train models with uncertainty and calibration where possible
- Generate a diverse candidate set that spans tradeoffs, not just top scores
- Run cheap falsification tests to eliminate obvious failures early
- Escalate survivors to more expensive experiments
- Update the models and decision rules with the new results
This loop is slower than “pick the top one,” but it is faster than chasing false hits for months.
Candidate Selection: Diversity Beats Single-Point Optimization
Teams often pick the single highest-scoring candidate, then discover the score was wrong.
A safer practice is to choose a portfolio:
- Candidates that are similar to known successes but improved in a key property
- Candidates that are structurally diverse to hedge against model bias
- Candidates that test different mechanistic hypotheses
- Candidates chosen specifically because the model is uncertain and you want to learn
This turns selection into risk management and learning.
Mechanism Confirmation: Keep the Claim Narrow Until It Is Earned
A model can suggest that a compound is “good,” but discovery requires you to know why.
Mechanism confirmation is where many projects lose clarity.
A disciplined workflow:
- Treats early hits as provisional signals, not as final answers
- Uses orthogonal assays to separate mechanism from artifact
- Tests whether the observed effect persists under controlled perturbations
- Keeps the narrative narrow until the evidence expands it
AI can help propose tests that discriminate between hypotheses, but the team must run those tests.
The “Evidence Pack” for a Candidate
Before a candidate is escalated, it should carry an evidence pack that makes review concrete.
A useful pack includes:
- The objective and which constraints are non-negotiable
- The predicted properties, with uncertainty, and which models produced them
- The nearest known neighbors and what is genuinely new
- Feasibility notes and expected failure points
- The planned assays and the falsification criteria
- A fallback plan if the first hypothesis fails
This format prevents the team from mistaking confidence for evidence.
Safety and Responsibility Must Be Part of the Workflow
A discovery workflow that optimizes only for potency can produce candidates that are unacceptable.
Responsible workflows include:
- Explicit safety and hazard constraints early
- Conservative interpretation of model outputs where uncertainty is high
- Human review gates for high-risk decisions
- Documentation that connects each claim to evidence
This is not bureaucracy. It is accountability.
What to Measure
The metrics that matter change by stage, but they should always connect to real outcomes.
Useful metrics include:
- Enrichment: does ranking produce more true hits per experiment?
- Calibration: do confidence estimates match reality?
- Robustness: does performance hold across batches, labs, or protocols?
- Cost per validated hit: the operational metric that matters
- Time-to-learn: how quickly the loop reduces uncertainty
A model that improves AUROC but does not improve enrichment is often not helping.
Why Honest Uncertainty Accelerates Progress
Teams often fear uncertainty because it sounds like weakness.
In discovery, uncertainty is information. It tells you where to spend budget.
A workflow that surfaces uncertainty:
- Avoids chasing false confidence
- Chooses experiments that teach more
- Builds claims that are harder to break
That is the difference between momentum and motion.
The Point of Evidence-Driven AI in Drug Discovery
The point is not to claim that AI “discovers drugs.”
The point is to build a disciplined process that turns a massive search into a smaller, testable set of hypotheses.
AI is valuable when it:
- Makes better bets
- Reduces wasted experiments
- Surfaces uncertainty honestly
- Leaves a trail of evidence you can defend
That is how speed becomes progress rather than noise.
Documentation That Protects the Science
Drug discovery teams often lose clarity because decisions are made quickly and then explained later.
A simple discipline prevents this: write the claim and the evidence at the time the decision is made.
Practical documentation includes:
- A short statement of the current hypothesis and what would falsify it
- The dataset and model versions used to justify the decision
- The planned experiments and the decision threshold for escalation
- A record of negative results and what they imply for the hypothesis
This keeps the narrative aligned with reality. It also makes collaboration easier, because new team members can see what was tried, what failed, and why the project believes what it believes.
External Replication as a Gate, Not a Victory Lap
A result that holds only within one lab environment is a fragile result.
When possible, treat external replication as a gate for high-confidence claims:
- Replicate key assays with a second operator or protocol variation
- Validate top candidates in a second lab or with an independent measurement method
- Re-check calibration and uncertainty on the external data
Even a small external check can catch hidden batch effects and workflow-specific artifacts. It is expensive, but it is often cheaper than building a program on a false signal.
Keep Exploring AI Discovery Workflows
If you want to go deeper on the ideas connected to this topic, these posts will help you build the full mental model.
• AI for Molecular Design with Guardrails
https://ai-rng.com/ai-for-molecular-design-with-guardrails/
• AI for Chemistry Reaction Planning
https://ai-rng.com/ai-for-chemistry-reaction-planning/
• Uncertainty Quantification for AI Discovery
https://ai-rng.com/uncertainty-quantification-for-ai-discovery/
• Benchmarking Scientific Claims
https://ai-rng.com/benchmarking-scientific-claims/
• Detecting Spurious Patterns in Scientific Data
https://ai-rng.com/detecting-spurious-patterns-in-scientific-data/
• Human Responsibility in AI Discovery
https://ai-rng.com/human-responsibility-in-ai-discovery/
Books by Drew Higgins
